Pharmaceuticals - CIS

In 2024, the projected revenue in the Pharmaceuticals market in CIS is expected to reach US$8.70bn.
The largest market within the pharmaceuticals industry is Oncology Drugs, which is projected to have a market volume of US$1.49bn in 2024.
Looking ahead, the revenue in the CIS pharmaceuticals market is expected to grow at an annual rate of 4.26% between 2024 and 2029, resulting in a market volume of US$10.72bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the pharmaceuticals market, with an estimated amount of US$630.30bn in 2024.
Despite economic challenges, the pharmaceutical market in CIS countries is experiencing steady growth due to an increased focus on healthcare and rising demand for innovative treatments.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in CIS is a rapidly growing industry with unique customer preferences and local special circumstances.

Customer preferences: Customers in the CIS region have a strong preference for generic drugs due to their affordability. This preference has been driven by the low purchasing power of the population in the region. Additionally, customers in the CIS region have a high demand for over-the-counter drugs due to the lack of access to healthcare professionals.

Trends in the market: The pharmaceuticals market in CIS is developing rapidly, with a focus on the development of new drugs and expansion of production facilities. The market is also seeing an increase in the number of joint ventures between local and international pharmaceutical companies. This trend has been driven by the need to access new technologies and expertise, as well as to expand into new markets.

Local special circumstances: The CIS region has a unique set of circumstances that impact the pharmaceuticals market. The region is characterized by a high burden of infectious diseases such as tuberculosis and HIV/AIDS, which has led to an increased demand for drugs to treat these conditions. Additionally, the region has a large population of elderly people who require medication for chronic conditions such as hypertension and diabetes.

Underlying macroeconomic factors: The pharmaceuticals market in CIS is influenced by a range of macroeconomic factors. The region has a large population of low-income individuals who have limited access to healthcare. This has created a demand for affordable medicines, which has led to the growth of the generic drug market. Additionally, the region has a large number of pharmaceutical manufacturing facilities, which has helped to drive the growth of the industry. Finally, the region has a relatively low cost of labor, which has made it an attractive location for pharmaceutical companies to set up production facilities.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.